Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Neuro Oncol. 2020 Nov 26;22(11):1602-1613. doi: 10.1093/neuonc/noaa117.
Twenty-five germline variants are associated with adult diffuse glioma, and some of these variants have been shown to be associated with particular subtypes of glioma. We hypothesized that additional germline variants could be identified if a genome-wide association study (GWAS) were performed by molecular subtype.
A total of 1320 glioma cases and 1889 controls were used in the discovery set and 799 glioma cases and 808 controls in the validation set. Glioma cases were classified into molecular subtypes based on combinations of isocitrate dehydrogenase (IDH) mutation, telomerase reverse transcriptase (TERT) promoter mutation, and 1p/19q codeletion. Logistic regression was applied to the discovery and validation sets to test for associations of variants with each of the subtypes. A meta-analysis was subsequently performed using a genome-wide P-value threshold of 5 × 10-8.
Nine variants in or near D-2-hydroxyglutarate dehydrogenase (D2HGDH) on chromosome 2 were genome-wide significant in IDH-mutated glioma (most significant was rs5839764, meta P = 2.82 × 10-10). Further stratifying by 1p/19q codeletion status, one variant in D2HGDH was genome-wide significant in IDH-mutated non-codeleted glioma (rs1106639, meta P = 4.96 × 10-8). Further stratifying by TERT mutation, one variant near FAM20C (family with sequence similarity 20, member C) on chromosome 7 was genome-wide significant in gliomas that have IDH mutation, TERT mutation, and 1p/19q codeletion (rs111976262, meta P = 9.56 × 10-9). Thirty-six variants in or near GMEB2 on chromosome 20 near regulator of telomere elongation helicase 1 (RTEL1) were genome-wide significant in IDH wild-type glioma (most significant was rs4809313, meta P = 2.60 × 10-10).
Performing a GWAS by molecular subtype identified 2 new regions and a candidate independent region near RTEL1, which were associated with specific glioma molecular subtypes.
25 种种系变异与成人弥漫性神经胶质瘤有关,其中一些变异已被证明与神经胶质瘤的特定亚型有关。我们假设,如果通过分子亚型进行全基因组关联研究(GWAS),可以发现更多的种系变异。
在发现组中使用了 1320 例神经胶质瘤病例和 1889 例对照,在验证组中使用了 799 例神经胶质瘤病例和 808 例对照。根据异柠檬酸脱氢酶(IDH)突变、端粒酶逆转录酶(TERT)启动子突变和 1p/19q 缺失的组合,将神经胶质瘤病例分类为分子亚型。在发现组和验证组中应用逻辑回归来检测变异与每种亚型的关联。随后使用全基因组 P 值阈值为 5×10-8 进行荟萃分析。
在 IDH 突变型神经胶质瘤中,染色体 2 上的 D-2-羟戊二酸脱氢酶(D2HGDH)内或附近的 9 个变异具有全基因组显著性(最显著的是 rs5839764,meta P=2.82×10-10)。进一步按 1p/19q 缺失状态分层,在 IDH 突变非缺失型神经胶质瘤中,D2HGDH 中的一个变异具有全基因组显著性(rs1106639,meta P=4.96×10-8)。进一步按 TERT 突变分层,染色体 7 上 FAM20C(家族与序列相似性 20,成员 C)附近的一个变异在具有 IDH 突变、TERT 突变和 1p/19q 缺失的神经胶质瘤中具有全基因组显著性(rs111976262,meta P=9.56×10-9)。在 IDH 野生型神经胶质瘤中,染色体 20 上靠近端粒伸长螺旋酶 1(RTEL1)的 GMEB2 内或附近的 36 个变异具有全基因组显著性(最显著的是 rs4809313,meta P=2.60×10-10)。
通过分子亚型进行 GWAS 鉴定出了与特定神经胶质瘤分子亚型相关的 2 个新区域和 RTEL1 附近的一个候选独立区域。